Denkert C, Lambertini C, Fasching PA, Pogue-Geile KL, et al. Biomarker Data From the Phase III KATHERINE Study of Adjuvant T-DM1 Versus Trastuzumab for Residual Invasive Disease After Neoadjuvant Therapy for HER2-Positive Breast Cancer. Clin Cancer Res 2023 Feb 2:CCR-22-1989. doi: 10.1158/1078-0432.CCR-22-1989.
PMID: 36730339